139
Trials as lead sponsor
Most active programmes
The drugs appearing most often across Sandoz's recently active trials. Comparator arms are excluded.
- GP20133 trials
- GME7512 trials
- SOK583A1 (40 mg/mL)2 trials
- HX575 recombinant human erythropoietin alfa2 trials
- LA-EP20062 trials
- Neulasta®2 trials
Top therapeutic areas
Conditions studied most often across Sandoz's recently active trials.
- Depression8 trials
- Hypertension5 trials
- Anemia4 trials
- Rheumatoid Arthritis4 trials
- Seasonal Allergic Rhinitis3 trials
- Pain3 trials
Sandoz trials
The 50 most significant of Sandoz's recently active trials, soonest estimated readout first.
Select any row for the full record; the change timeline unlocks with tracking.
| Trial | Phase | Stability | Status | Enrollment | Est. readout |
|---|---|---|---|---|---|
| Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple SclerosisNCT06847724CYB704 | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 183 est. | Nov 2026 |
| A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda® in Participants With Stage II and III MelanomaNCT06153238GME751 | Phase 1 | Locked · track to reveal | Completed | 322 est. | 5 May 2026 |
| Study to Evaluate the Therapeutic Equivalence and Safety of Fluticasone Furoate and Vilanterol Inhalation Powder 100 mcg/25 mcg and BREO ELLIPTA 100 mcg/25 mcg in Participants With AsthmaNCT07223294Fluticasone furoate and vilanterol inhalation powder | Phase 3 | Locked · track to reveal | StoppedWithdrawn | 0 est. | 21 Apr 2026 |
| A Study to Compare Efficacy, Safety, and Immunogenicity of GME751 and EU-authorized Keytruda in Adult Participants With Untreated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)NCT06159790GME751 | Phase 3 | Locked · track to reveal | Completed | 218 est. | 16 Mar 2026 |
| Integrated Pharmacokinetics (PK)/Efficacy, Safety, and Immunogenicity Study to Demonstrate Similarity of JPB898, a Proposed Biosimilar to Nivolumab, to Opdivo® in Combination With Yervoy®NCT06587451JPB898 (Induction and Maintenance) | Phase 3 | Locked · track to reveal | StoppedTerminated | 52 est. | 23 Jan 2026 |
| HYRISSObservational Study, to Assess Treatment Retention of an Adalimumab Biosimilar (Hyrimoz®) in IBD Patients in Real Life SettingNCT05633771Hyrimoz | — | Not yet scored | OngoingActive, not recruiting | 562 est. | 15 Dec 2025 |
| Efficacy and Safety of the Combination of Acetylcysteine, Paracetamol and Phenylephrine for the Treatment of Common ColdNCT05070650Acetylcysteine | Phase 3 | Locked · track to reveal | StoppedWithdrawn | 0 est. | 30 Apr 2025 |
| SMARTNon-interventional, Long-term Safety Data Collection of Zarzio® / Filgrastim HEXAL® in Stem Cell DonorsNCT01766934 | — | Not yet scored | Completed | 245 est. | 29 Aug 2024 |
| Study to Compare the Pharmacokinetics of Fixed-Dose Combination of Mometasone + Azelastine Nasal Spray to Mometasone and Azelastine Nasal Sprays in Adolescents and Young Adults With Seasonal Allergic RhinitisNCT05887843Mometasone + Azelastine | Phase 1 | Locked · track to reveal | StoppedTerminated | 38 est. | 8 Sept 2023 |
| Prospective, Randomized, Multinational, Multicenter, Double-blind, Placebo and Active Controlled Trial in 4 Parallel-groups of Patients Suffering From Seasonal Allergic RhinitisNCT05311475Mometasone | Phase 3 | Locked · track to reveal | Completed | 669 est. | 20 Jun 2023 |
| Efficacy and Safety of Azelastine +Mometasone , Nasal Spray, 140 mcg + 50 mcg, (Sandoz d.d., Slovenia) and Momat Rino Advance, Nasal Spray, 140 mcg + 50 mcg, (Glenmark, India) Administered as a Monotherapy to Patients With Seasonal Allergic Rhinitis.NCT05590598Azelastine + Mometazone, nasal spray | Phase 3 | Locked · track to reveal | Completed | 472 est. | 14 Jun 2023 |
| Study of the Efficacy and Safety of Broncho-munal®, Capsules, 7 mg for the Treatment of Acute Uncomplicated Respiratory Tract InfectionsNCT05588804Broncho-munal® | Phase 3 | Locked · track to reveal | Completed | 556 est. | 18 Dec 2022 |
| A Crossover Bioequivalence Study of Olaparib Tablets, 150 mg (Lek Pharmaceuticals d.d.) and Lynparza® (Olaparib) Tablets 150 mg (AstraZeneca Pharmaceuticals LP), in Patients With Breast Cancer Gene (BRCA) Mutated Ovarian Cancer, Recurrent Ovarian Cancer or Metastatic Breast CancerNCT05258747Olaparib tablets, 150 mg | Phase 1 | Locked · track to reveal | Completed | 70 est. | 20 Oct 2022 |
| Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial KitNCT05282004SOK583A1 | Phase 3 | Locked · track to reveal | Completed | 36 est. | 7 Sept 2022 |
| MylightPhase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea® in Patients With Neovascular Age-related Macular DegenerationNCT04864834SOK583A1 (40 mg/mL) | Phase 3 | Locked · track to reveal | Completed | 485 est. | 7 Jul 2022 |
| Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Prefilled SyringeNCT05161806SOK583A1 (40 mg/mL) | Phase 3 | Locked · track to reveal | Completed | 30 est. | 4 May 2022 |
| Study Investigating PK, PD, Efficacy, Safety, and Immunogenicity of Biosimilar Denosumab (GP2411) in Patients With Postmenopausal OsteoporosisNCT03974100GP2411 | Phase 3 | Locked · track to reveal | Completed | 527 est. | 22 Apr 2022 |
| Safety and Efficacy of Omnitrope® (rhGH) in Short Children Born Small for Gestational Age (SGA)NCT00537914Omnitrope | Phase 4 | Locked · track to reveal | Completed | 278 est. | 25 Mar 2022 |
| Efficacy and Safety of Acetylcysteine for the Treatment of Acute Uncomplicated RhinosinusitisNCT04123405acetylcysteine | Phase 3 | Locked · track to reveal | Completed | 944 est. | 20 Apr 2021 |
| Study of LRG-002 Hard Capsules (Lek d.d., Slovenia) Used in the Prophylaxis of Antibiotic-associated Diarrhea in Adults.NCT04321460LRG-002 | Phase 3 | Locked · track to reveal | Completed | 520 est. | 4 Jan 2021 |
| Study to Test the Hypothesis of Non-inferior Efficacy and Safety of Ferrum Lek® (Iron (III) Hydroxide Polymaltosate), 100 mg Chewable Tablets (Lek d.d., Slovenia), as Compared With MALTOFER® (Vifor S.A., Switzerland), in Subjects With Mild and Moderate Iron Deficiency Anemia.NCT03993288Ferrum Lek® (iron (III) hydroxide polymaltosate), 100 mg chewable tablets (Lek d.d., Slovenia) | Phase 3 | Locked · track to reveal | Completed | 267 est. | 18 Jun 2020 |
| GIANTReal-world Study of Anti-TNFa Treatment Regimes of Hyrimoz or Zessly in Patients With Crohn´s DiseaseNCT03890445 | — | Not yet scored | Completed | 63 est. | 8 May 2020 |
| TODAYStudy to Compare Pharmacokinetics of Tacrolimus Prolonged-release (PR) Capsules and Advagraf® PR Capsules in Stable Kidney Transplant Patients.NCT03978494Advagraf® | Phase 1 | Locked · track to reveal | StoppedWithdrawn | 0 est. | 3 May 2020 |
| An Open, Randomised, Single Dose, 2-period, 2-sequence Crossover Adhesion Study of Two Different Transdermal Patches Containing Rotigotine.NCT04183634Rotigotine TTS (Test) | Phase 1 | Locked · track to reveal | StoppedTerminated | 31 est. | 16 Mar 2020 |
| Study of Loteprednol Etabonate in Adults Undergoing Bilateral Cataract SurgeryNCT03531697Generic Loteprednol Etabonate | Phase 1 | Locked · track to reveal | Completed | 381 est. | 7 Sept 2019 |
| This Was a Clinical Study Investigating the Moisturization and Desquamation Effect of AmLactin® Rapid Relief Restoring Lotion + Ceramides on Dry Skin in Healthy Female Volunteers. AmLactin® Rapid Relief is an Over-the-counter CosmeticNCT04085809AmLactin® Rapid Relief | Na | Locked · track to reveal | Completed | 56 est. | 8 Apr 2019 |
| In Vivo Performance of Oral Liquid Formulations of Budesonide in the Fasted State in Healthy SubjectsNCT05429775Budesonide | Phase 1 | Locked · track to reveal | Completed | 12 est. | 29 Jan 2019 |
| A Study Comparing Two Ferric Carboxymaltose Formulations in Patients With Iron Deficiency AnemiaNCT03399084Ferric carboxymaltose | Phase 1 | Locked · track to reveal | Completed | 71 est. | 15 Jan 2019 |
| SGALong-term Safety Follow-up After Growth Hormone Treatment of Short Children Born Small for Gestational AgeNCT01491854Bloodsampling | Na | Locked · track to reveal | StoppedTerminated | 130 est. | 31 Oct 2018 |
| A Study Comparing Two Rifaximin Tablets in Patients With Travelers' Diarrhea.NCT02920242Rifaximin (Sandoz GmbH) tablet | Phase 3 | Locked · track to reveal | StoppedTerminated | 28 est. | 23 May 2017 |
| Clinical Study for Comparative Assessment of Efficacy and Safety of Angal S, Topical Spray and ANTI-ANGIN® FORMULA, Topical Metered Spray in Treatment of Patients With Uncomplicated Acute Infectious and Inflammatory Diseases of the Pharynx, Accompanied by a Sore ThroatNCT03095508Angal S, topical spray [Menthol] | Phase 3 | Locked · track to reveal | Completed | 229 est. | 8 May 2017 |
| A Local Clinical Study for the Comparative Evaluation of Efficacy and Safety of Angal, Lozenges [Menthol] and ANTI-ANGIN® FORMULA, Lozenges, in Treatment of Patients With a Sore ThroatNCT03095521Angal, lozenges [menthol], | Phase 3 | Locked · track to reveal | Completed | 228 est. | 7 May 2017 |
| ADMYRAClinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid ArthritisNCT02744755Adalimumab - GP2017 | Phase 3 | Locked · track to reveal | Completed | 353 est. | 31 Jan 2017 |
| EQUIRAComparative Efficacy and Safety Study of GP2015 and Enbrel® in Patients With Rheumatoid ArthritisNCT02638259GP2015 | Phase 3 | Locked · track to reveal | Completed | 376 est. | 29 Dec 2016 |
| ASSIST-RTGP2013 Treatment in Patients With Active Rheumatoid Arthritis, Previously Treated With Rituxan® or MabThera®NCT02514772GP2013 - A Proposed biosimilar rituximab | Phase 3 | Locked · track to reveal | Completed | 107 est. | Jul 2016 |
| Pramipexole and Bromocriptine on Nonmotor Symptoms of Early Parkinson's DiseaseNCT01673724pramipexole | Phase 4 | Locked · track to reveal | Completed | 121 est. | 23 May 2016 |
| GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard TherapyNCT01274182GP2013 | Phase 1 | Locked · track to reveal | Completed | 312 est. | Jan 2016 |
| Non-interventional-study With Tacrolimus Sandoz© Capsules for Prophylaxis of Renal Graft RejectionNCT01353417In this observational study no study specific intervention is planned | — | Not yet scored | Completed | 102 est. | 31 Aug 2015 |
| ADACCESSStudy to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Adalimumab (GP2017) and HumiraNCT02016105GP2017 Adalimumab | Phase 3 | Locked · track to reveal | Completed | 465 est. | Jul 2015 |
| ASSIST_FLGP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma (ASSIST_FL)NCT01419665GP2013 | Phase 3 | Locked · track to reveal | Completed | 629 est. | 10 Jul 2015 |
| REIN-PDRemission of ICD by Switching Dopamine Agonist to Levodopa/CarbidopaNCT01683253Levodopa/Carbidopa(200mg/50mg) | Phase 4 | Locked · track to reveal | Completed | 150 est. | Dec 2014 |
| SENSEHX575 Epoetin Alfa Subcutaneously (s.c.) in Chronic Kidney Disease (CKD)NCT01576341HX575 epoetin alfa (Sandoz) | Phase 3 | Locked · track to reveal | Completed | 417 est. | Oct 2014 |
| GP2013 in Japanese Patients With CD20 Positive Low Tumor Burden Indolent B-cell Non-Hodgkin's LymphomaNCT01933516GP2013 | Phase 1 | Locked · track to reveal | Completed | 6 est. | Aug 2014 |
| ACCESSStudy to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin AlfaNCT01693029HX575 epoetin alfa | Phase 3 | Locked · track to reveal | Completed | 435 est. | May 2014 |
| PROTECT2Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-FilgrastimNCT01516736LA-EP2006 | Phase 3 | Locked · track to reveal | Completed | 308 est. | Aug 2013 |
| PROTECT-1Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Neulasta®NCT01735175LA-EP2006 | Phase 3 | Locked · track to reveal | Completed | 316 est. | May 2013 |
| A Study Comparing Two Fluticasone Furoate Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic RhinitisNCT01279057Fluticasone furoate 27.5 mcg/actuation nasal spray (Lek Pharmaceuticals) | Phase 3 | Locked · track to reveal | Completed | 727 est. | 8 Feb 2011 |
| EPO-PASSPost-authorization Safety Study in CKD Subjects Receiving HX575 i.v.NCT00632125HX575 recombinant human erythropoietin alfa | Phase 4 | Locked · track to reveal | Completed | 1,695 est. | Mar 2010 |
| A Study Comparing the Clinical Equivalence of Two Mometasone Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic RhinitisNCT01038427Mometasone furoate 50 mcg/actuation nasal spray (Lek Pharmaceuticals) | Phase 3 | Locked · track to reveal | Completed | 795 est. | 16 Feb 2010 |
| Pilot Study to Examine the Post-Dose Changes in Exhaled Nitric Oxide (eNO) Following Treatment With Fluticasone Propionate (FP)/Salmeterol (SAL) Combination Product AdvairNCT00927758fluticasone propionate/salmeterol (Flu/Sal) : 100mcg/50mcg, 250mcg/50mcg,500mcg/50 mcg | Phase 2 | Locked · track to reveal | Completed | 105 est. | Dec 2009 |